Cherwell Releases New Redipor Prepared Microbiological Media Product Information
![](/46/pdcnewsitem/03/42/69/yniQ4YzhjVaRMRx.jpg)
Cherwell Laboratories has announced the availability of its 2015 Redipor prepared microbiological media price list. The extensive Redipor range, manufactured at Cherwell’s ISO9001 registered site in Bicester offers ready-to-use media, including Petri dishes, contact plates, bottles and broth bags, designed to meet the rigorous requirements of the pharmaceutical and related industries.
With over 40 years’ experience, Cherwell has built a strong reputation for providing high-quality products alongside a friendly, customer-focused service. Despite significant company growth, fuelled by increasing demand for Redipor prepared media throughout the UK and across Europe, Cherwell have retained flexible production methods and managed stock levels, ensuring they can continue to deliver cost effective, timely solutions for customers.
Offering an extensive selection of both industry standard products and those with a unique formulation or presentation, the Redipor range provides a flexible solution for environmental monitoring, sterility testing of products, operator validation and process validation. The range includes petri dishes (55 mm, 90 mm and 140 mm) and contact plates, plus bottled media, broth bags and ampoules, with all products subjected to a full array of QC tests, including comprehensive growth tests. Cherwell can also discuss specific requirements and work with individual customers to ensure their needs are met.
“As a family-owned business, we understand the importance of maintaining good communication and relations with all our customers to ensure we continue to meet their exact requirements,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Over the years, the reputation of the Redipor brand has been built on our flexibility and willingness to adapt efficiently to changes in both customer and regulatory expectations.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance